AUCATZYL launch concentration
The company currently depends on a single commercial product, so slower adoption or access issues would materially affect revenue.
- Scope
- U.S. commercial launch
- Materiality
- high
Autolus Therapeutics plc
Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies, with its first approved product, AUCATZYL, now generating U.S. product revenue. The company’s core platform is CAR T-cell engineering, which it uses to design therapies for hematologic cancers and to advance a broader pipeline of product candidates. Autolus also relies on translational research collaborations, including with University College London, to support early-stage development. The business remains in an investment-and-launch phase, with commercial execution in the U.S. alongside ongoing clinical development and manufacturing scale-up in the U.K.
−347,9 %
−27,8 %
−381,4 %
+644,9 %
5.94
5.48
| % | |
|---|---|
| Commercial cell therapy | 100% Approved CAR T therapy sold in the U.S. for eligible cancer patients. |
| Clinical-stage pipeline | 0% Investigational CAR T programs advancing through preclinical and clinical development. |
| Collaborative research and licensing | 0% Research collaborations and license arrangements that support pipeline creation and development. |
| Manufacturing and supply chain operations | 0% Cell therapy manufacturing, release, and distribution activities supporting commercial and clinical supply. |
Autolus sells AUCATZYL through U.S. cancer treatment centers, so its direct customers are healthcare providers and...
- Cancer treatment centersprimary
Hospitals and oncology centers buy and administer AUCATZYL for eligible patients; they matter because the therapy is delivered through activated sites of care.
- Payors and government programsprimary
Commercial insurers and programs such as Medicaid, TriCare, DoD, VA, and 340B influence coverage, reimbursement, and net realized pricing.
- Oncology physicians and care teamssecondary
Specialists choose CAR T therapy for patients based on clinical profile, access, and treatment pathway suitability.
- Patients with hematologic cancerssecondary
Patients are the end beneficiaries of the therapy; demand depends on diagnosis, eligibility, and access to treatment centers.
Autolus currently generates product revenue in the United States, where AUCATZYL has been launched and where the...
- •United States is the commercial revenue market for AUCATZYL
- •U.S. treatment-center rollout drives patient access and sales growth
- •United Kingdom is the main manufacturing base for commercial and clinical supply
- •U.K. VAT treatment affects recoverability of input VAT and cash costs
- •Global suppliers provide biological materials, APIs, and equipment
- •International trade policy can affect supply continuity and manufacturing costs
Autolus is focused on converting AUCATZYL from launch into a scaled commercial franchise in the United States while...
01
Scale the U.S. AUCATZYL launchshort-term
Commercial success depends on center activation, patient access, and reimbursement coverage.
02
Strengthen manufacturing and supply chain executionmedium-term
CAR T therapies are operationally complex and require reliable commercial and clinical supply.
03
Advance the pipeline beyond AUCATZYLmedium-term
Long-term value depends on additional product candidates and broader platform validation.
Autolus faces the typical risks of a cell-therapy company: clinical development uncertainty, manufacturing complexity,...
Reimbursement and pricing pressure
Coverage decisions, government program pricing, and rebate/chargeback mechanics directly reduce net product revenue.
- Scope
- Medicaid, TriCare, DoD, VA, 340B
- Materiality
- high
Manufacturing and supply chain disruption
CAR T products require specialized materials, outsourced services, and controlled manufacturing, which can be interrupted or become more expensive.
- Scope
- U.K. manufacturing and global suppliers
- Materiality
- high
Clinical pipeline failure
Future value depends on successful development of additional product candidates, which may not reach approval.
- Scope
- Preclinical and clinical CAR T programs
- Materiality
- high
International trade policy and tariffs
Tariffs or export restrictions could increase cost of goods and delay commercial or clinical supply.
- Scope
- Cross-border sourcing and U.S. import flows
- Materiality
- medium
ASC 606 point-in-time revenue recognition
Can shift revenue between quarters and affect comparability
Gross-to-net deductions
Directly affects reported product revenue and accrued liabilities
Manufacturing cost classification
Distorts gross margin trends across launch periods
Deferred revenue and accrual estimates
Creates balance-sheet sensitivity to estimate changes
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Arcellx, Inc.
Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
BioAtla, Inc.
BCAB · Biological Products, (No Diagnostic Substances)
Cartesian Therapeutics, Inc.
RNAC · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
: 11/08/2026